Savolainen Markku J, Karlsson Antti, Rohkimainen Samppa, Toppila Iiro, Lassenius Mariann I, Falconi Carlos Vaca, Uusi-Rauva Kristiina, Elomaa Kaisa
Oulu University Hospital, PO Box 10, 90029 OYS, Oulu, Finland.
Auria Biobank, Turku University Hospital, University of Turku, PO Box 52, 20521 Turku, Finland.
Mol Genet Metab Rep. 2021 Feb 9;27:100725. doi: 10.1016/j.ymgmr.2021.100725. eCollection 2021 Jun.
Gaucher disease (GD) is a rare inherited multiorgan disorder, yet a diagnosis can be significantly delayed due to a broad spectrum of symptoms and lack of disease awareness. Recently, the prototype of a GD point-scoring system (PSS) was established by the Gaucher Earlier Diagnosis Consensus (GED-C) initiative, and more recently, validated in Gaucher patients in UK. In our study, the original GED-C PSS was tested in Finnish GD patients. Furthermore, the feasibility of point scoring large electronic health record (EHR) data set by data mining to identify potential undiagnosed GD cases was evaluated.
This biobank study was conducted in collaboration with two Finnish biobanks. Five previously diagnosed Finnish GD patients and ~ 170,000 adult biobank subjects were included in the study. The original PSS was locally adjusted due to data availability issues and applied to the Finnish EHR data representing special health care recordings.
All GD patients had high levels of the biomarker lyso-Gb1 and deleterious mutations. One patient was a compound heterozygote with a novel variant, potentially pathogenic mutation. Finnish EHR data allowed the retrospective assessment of 27-30 of the 32 original GED-C signs/co-variables. Total point scores of GD patients were high but variable, 6-18.5 points per patient (based on the available data on 28-29 signs/co-variables per patient). All GD patients had been recorded with anaemia while only three patients had a record of splenomegaly. 0.72% of biobank subjects were assigned at least 6 points but none of these potential "GD suspects" had a point score as high as 18.5. Splenomegaly had been recorded for 0.25% of biobank subjects and was associated with variable point score distribution and co-occurring ICD-10 diagnoses.
This study provides an indicative GED-C PSS score range for confirmed GD patients, also representing potential mild cases, and demonstrates the feasibility of scoring Finnish EHR data by data mining in order to screen for undiagnosed GD patients. Further prioritisation of the "GD suspects" with more developed algorithms and data-mining approaches is needed.
This study was funded by Shire (now part of Takeda).
戈谢病(GD)是一种罕见的遗传性多器官疾病,但由于症状范围广泛且对该疾病缺乏认识,诊断可能会显著延迟。最近,戈谢病早期诊断共识(GED-C)倡议建立了GD积分系统(PSS)的原型,并且最近在英国的戈谢病患者中进行了验证。在我们的研究中,对原始的GED-C PSS在芬兰戈谢病患者中进行了测试。此外,还评估了通过数据挖掘对大型电子健康记录(EHR)数据集进行积分以识别潜在未确诊GD病例的可行性。
这项生物样本库研究是与两个芬兰生物样本库合作进行的。研究纳入了5名先前诊断的芬兰戈谢病患者和大约170,000名成年生物样本库受试者。由于数据可用性问题,对原始PSS进行了局部调整,并应用于代表特殊医疗记录的芬兰EHR数据。
所有戈谢病患者的生物标志物溶酶体葡萄糖脑苷脂(lyso-Gb1)水平都很高,并且存在有害突变。一名患者是具有新变体(可能致病的突变)的复合杂合子。芬兰EHR数据允许对32个原始GED-C体征/协变量中的27 - 30个进行回顾性评估。戈谢病患者的总积分很高但存在差异,每位患者6 - 18.5分(基于每位患者28 - 29个体征/协变量的可用数据)。所有戈谢病患者都有贫血记录,而只有3名患者有脾肿大记录。生物样本库受试者中有0.72%被赋予至少6分,但这些潜在的“戈谢病疑似病例”中没有一个的积分高达18.5分。生物样本库受试者中有0.25%有脾肿大记录,并且与积分分布差异和同时出现的国际疾病分类第十版(ICD-10)诊断相关。
本研究为确诊的戈谢病患者提供了一个指示性的GED-C PSS积分范围,也代表了潜在的轻症病例,并证明了通过数据挖掘对芬兰EHR数据进行积分以筛查未确诊戈谢病患者的可行性。需要用更先进的算法和数据挖掘方法对“戈谢病疑似病例”进行进一步排序。
本研究由夏尔公司(现为武田制药的一部分)资助。